Michael Gelband’s Twist Bioscience TWST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.35M Buy
+51,999
New +$3.38M 0.03% 472
2025
Q3
Sell
-471,829
Closed -$17.4M 2037
2025
Q2
$17.4M Buy
471,829
+43,092
+10% +$1.49M 0.15% 134
2025
Q1
$16.8M Buy
428,737
+389,437
+991% +$17.5M 0.17% 118
2024
Q4
$1.83M Buy
+39,300
New +$1.78M 0.01% 748
2024
Q1
Sell
-10,237
Closed -$377K 1974
2023
Q4
$377K Buy
+10,237
New +$237K ﹤0.01% 1113
2023
Q3
Sell
-18,653
Closed -$382K 2160
2023
Q2
$382K Buy
+18,653
New +$279K ﹤0.01% 1450
2023
Q1
Sell
-32,179
Closed -$766K 2139
2022
Q4
$766K Buy
32,179
+13,959
+77% +$405K 0.01% 1038
2022
Q3
$642K Buy
+18,220
New +$774K 0.01% 1279
2022
Q1
Sell
-4,887
Closed -$378K 2693
2021
Q4
$378K Buy
+4,887
New +$502K ﹤0.01% 1559
2021
Q2
Sell
-5,850
Closed -$725K 2816
2021
Q1
$725K Buy
+5,850
New +$888K 0.01% 1117

Other funds holding TWST

Michael Gelband's TWST Position: Q2 2026 in Review

Michael Gelband opened a new position in Twist Bioscience (TWST) in Q2 2026: 51,999 shares worth $5.35M. The stake represents 0.03% of the portfolio and ranks #472 among its holdings. This is a return to the name: Michael Gelband previously reported a position in TWST as recently as Q2 2025.

Michael Gelband first reported a position in TWST in Q1 2021 and has held it in 10 quarters since. The position peaked at $17.4M in Q2 2025. 334 funds tracked by Wall St. Rank hold TWST as of Q2 2026.

  • Michael Gelband held 51,999 shares of Twist Bioscience worth $5.35M as of Q2 2026.
  • Twist Bioscience was a new Michael Gelband position in Q2 2026.
  • Twist Bioscience made up 0.03% of Michael Gelband's portfolio in Q2 2026, its #472 holding.
  • Michael Gelband first reported a position in Twist Bioscience in Q1 2021 and has held it in 10 quarters since.
  • Michael Gelband's Twist Bioscience position peaked at $17.4M in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.